ArticleBMJ open2019
Burden of heart failure in Flemish general practices: a registry-based study in the Intego database.
Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review.Current heart failure reports · 2022Pooled it
- Effects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis.Journal of the renin-angiotensin-aldosterone system : JRAASPooled it
- The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.Diabetes, obesity & metabolism · 2022Trial
- Genetic and Molecular Mechanisms of Non-Ischemic Heart Failure with Preserved Ejection Fraction: Pathway Crosstalk, Translational Implications, and Regional Genetic Context.International journal of molecular sciences · 2026Review
- Adherence to plant-based diet and risk of heart failure among middle-aged and older population.Frontiers in nutrition · 2026Article
- Global trends and age-period-cohort analysis for the disability adjusted life years and mortality of type 2 diabetes mellitus due to diet high in sugar-sweetened beverages.Nutrition journal · 2025Article
- Data resource profile: the Intego-II primary care database.International journal of epidemiology · 2025Article
- A population analysis of delayed ejaculation using a claims database: characteristics and national trends in prevalence, incidence, and pharmacotherapy.International journal of impotence research · 2025Article
- The Nutritional Status of Patients with Heart Failure and Its Impact on Patient' Outcomes-The Center's Own Experience.Nutrients · 2025Article
- Exercise Training in Heart Failure: Current Evidence and Future Directions.Journal of clinical medicine · 2025Review
- Disease Burden of Type 2 Diabetes Among Young Adults in Asia: An Analysis From the Global Burden of Disease Study 2021.Journal of diabetes research · 2025Article
- Global epidemiology of heart failure.Nature reviews. Cardiology · 2024Review
- The Role of Coagulation in Heart Failure: A Literature Review.Current heart failure reports · 2024Review
- Medication and Outcome in Older Heart Failure Patients: Results from a Prospective Cohort Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Clinical markers in heart failure: a narrative review.The Journal of international medical research · 2024Review
- Sex difference in incidence and risk factors of hospitalization for heart failure, and subsequent mortality: findings from the China PEACE million persons project.BMC public health · 2023Article
- New onset heart failure with reduced ejection fraction management: single center, real-life Tunisian experience.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Article
- Prevalence of Heart Failure Stages in a Universal Health Care System: The Military Health System Experience.The American journal of medicine · 2023Observational
- Lagging behind the Western countries: the knowledge gaps of gender differences in heart failure in Asia.ESC heart failure · 2023Review
- Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran.Health economics review · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the prevalence and incidence of heart failure (HF) stages A to C/D and their evolution over a 16-year period. Additionally, trends in comorbidities and cardiovascular (CV) treatment in patients with HF were studied in the same period.
designRegistry-based study.
settingPrimary care, Flanders, Belgium.
participantsData were obtained from Intego, a morbidity registration network in which 111 general practitioners of 48 practices collaborate. In the study period between 2000 and 2015, data from 165 796 unique patients aged 45 years and older were available. OUTCOME MEASURES: Prevalence and incidence were calculated for HF stage A, B and C/D by gender. Additionally, the trend in age-standardised prevalence and incidence rates between 2000 and 2015 was analysed with joint-point regression. The same model was used to study trends in comorbidity profiles in incident HF cases and trends in cardiovascular medication in prevalent HF cases.
resultsWe found a downward trend in the incidence and prevalence of HF stage C/D in Flemish general practice between 2000 and 2015, whereas the prevalence and incidence of stage A and B increased. The burden of comorbidities in incident HF cases increased during the study period, as shown by an increasing disease count (p<0.001). The prescription of cardiovascular medication such as renin-angiotensin-aldosterone system blockade, β-blockers and statins showed a sharp increase in the first part of the study period (2000-2008).
conclusionAge-standardised incidence and prevalence of HF stage C/D showed a slightly downward trend over the past 16 years, probably due to the sharp increase in cardiovascular treatment. However, the increasing age-standardised incidence and prevalence of stage A and B, as precursors of symptomatic HF, together with a rising comorbid burden, highlights the challenges we are still facing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.